Project description
Furthering the field of protein drug-conjugates
Portugal’s Institute of Molecular Medicine (IMM) will receive a scientific boost in its work on human genome research and developing new therapeutic approaches. The EU-funded SIMICA project will integrate the IMM into the European circle of research excellence institutions via a sustainable science, technology and innovation network comprising internationally-leading organisations in the field of protein drug-conjugates. SIMICA’s strategy is based on science- and innovation-driven clustering. It will focus on designing and constructing the next generation of chemically-defined and innovative protein drug-conjugates for the targeted treatment of serious conditions such as cancer. It will also offer training and mentoring opportunities for IMM’s young researchers.
Fields of science
Programme(s)
- H2020-EU.4.b. - Twinning of research institutions Main Programme
Topic(s)
Funding Scheme
CSA - Coordination and support action
Coordinator
1649 028 Lisboa
Portugal
See on map
Participants (4)
1030 Wien
See on map
2333 ZA Leiden
See on map
2573 HT 'S-gravenhage
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
CB2 1TN Cambridge
See on map